Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
React to this article
Latest news
Date Title
09:24p THE KEG ROYALTIES INCOME FUND : Announces February 2016 Cash Distribution
09:22p SEARS : Kmart will close Virginia Beach store on General Booth Blvd.
09:22p RURALCO : Change of Director's Interest Notice
09:21p CTI BIOPHARMA : Goldberg Law PC Announces Securities Class Action Lawsuit against CTI BioPharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09:20p Scramble for safety boosts yen, gold and bonds
09:18p AEROJET ROCKETDYNE : See Rocketdyne-powered payload blast off from Vandenberg AFB
09:17p Twitter's CEO making big product changes, but users not wowed
09:16pDJASIA MARKETS : Hong Kong Stocks Sputter And Fizzle As Market Reopens
09:13p SYNCHRONY FINANCIAL : plans to hire 200 in Kettering
09:11p SOUTHERN CALIFORNIA GAS : Aliso Canyon Gas Leak - Incident Update - February 10, 2016
Latest news
Advertisement
Hot News 
UBS : Asset Management and Morningstar Collaboration in the Defined Contribution Market Passes Milestone
TANGENT COMMUNICATIONS : Recommended Cash Offer
HORNBY : Warns On Annual Loss And Banking Covenants After Weak January
ANIMALCARE : Profit Down In First Half As Lower-Margin Revenue Rises
GREAT WESTERN MINING : Minister unable to set electrification date for Swansea
Most Read News
07:49p CITY OF FLINT MI : Mayor Weaver’s Response to Gov. Snyder’s Budget Proposal
07:49p AUSTRALIAN GREENS : Victorians being punished for ditching the East West toll road
07:47p Tesla expects to become profitable in 2016, shares surge
06:16p GOODMAN PLUS : Industrial Trust Half Year Accounts ...
07:54p CALED CALIFORNIA ASSOCIATION FOR LOCAL ECONOMIC : Free Workshop: Access to Growth Capital with NOWaccount & Social Media Marketing
Most recommended articles
09:20p Scramble for safety boosts yen, gold and bonds
09:17p Twitter's CEO making big product changes, but users not wowed
09:16pDJASIA MARKETS : Hong Kong Stocks Sputter And Fizzle As Market Reopens
09:05pDJHong Kong Market Reopens to Steep Falls
09:02pDJASIAN SHARES : Hong Kong Market Reopens to Steep Falls